CMEOF (Creo Medical Group) GF Value Rank: 0 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CMEOF Creo Medical Group PLC CMEOF
52 GF Score
Price $0.20
GF Value $0.25
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group GF Value Rank?

Creo Medical Group has the GF Value Rank of 0.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Creo Medical Group GF Value Rank Related Terms

CMEOF
52GF Score
Creo Medical Group PLC CMEOF
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Creo Medical Group (CMEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.

Key valuation signals for CMEOF:

  • GF Value Rank: 0
  • GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Creo Medical Group Business Description

Other Exchanges CREO:UK
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
52GF Score

Get the complete analysis for CMEOF

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.20
Price
$0.25
GF Value